Abstract
NAMI-A is a novel ruthenium-containing experimental anticancer agent. We have developed and validated a rapid and sensitive analytical method to determine NAMI-A in human plasma, plasma ultrafiltrate and urine using atomic absorption spectrometry with Zeeman correction. The sample pretreatment procedure is straightforward, involving only dilution with an appropriate hydrochloric acid buffer-solution. Because the response signal of the spectrometer depended on the composition of the sample matrix, in particular on the amount of human plasma in the sample, all unknown samples were diluted to match the matrix composition in which the standard line was prepared (plasma-buffer 1 : 10 v/v). This procedure enabled the measurement of samples of different biological matrices in a single run. The validated range of determination was 1.1–220 μM NAMI-A for plasma and urine, and 0.22–44 μM for plasma ultrafiltrate. The lower limit of detection was 0.85 μM in plasma and urine and 0.17 μM in plasma ultrafiltrate. The lower limit of quantitation was 1.1 and 0.22 μM, respectively. The performance of the method, in terms of precision and accuracy, was according to the generally accepted criteria for validation of analytical methodologies. The applicability of the method was demonstrated in a patient who was treated in a pharmacokinetic phase I trial with intravenous NAMI-A.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 1 September 2000 / Revised: 1 November 2000 / Accepted: 12 November 2000
Rights and permissions
About this article
Cite this article
Crul, M., van den Bongard, H., Tibben, M. et al. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 369, 442–445 (2001). https://doi.org/10.1007/s002160000662
Issue Date:
DOI: https://doi.org/10.1007/s002160000662